Gyre Therapeutics, Inc. SEC filings GYRE
Gyre Therapeutics, Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Sep 10, 2013. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Aug 3, 2026 | — |
| EFFECT | Filing | Nov 22, 2024 | — |
| CORRESP | Letter to the SEC | Nov 20, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 20, 2024 | — |
| RW | Filing | Jul 12, 2024 | — |
| RW | Filing | Jul 12, 2024 | — |
| RW | Filing | Nov 29, 2023 | — |
| D | Filing | Nov 13, 2023 | — |
| EFFECT | Filing | Oct 27, 2023 | — |
| CORRESP | Letter to the SEC | Oct 24, 2023 | — |
| CORRESP | Letter to the SEC | Oct 13, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 3, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 20, 2023 | — |
| CORRESP | Letter to the SEC | Jul 12, 2023 | — |
| PRER14A | Filing | Jul 12, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 10, 2023 | — |
| CORRESP | Letter to the SEC | Jun 26, 2023 | — |
| PRER14A | Filing | Jun 26, 2023 | — |
| UPLOAD | Letter from the SEC | May 31, 2023 | — |
| CORRESP | Letter to the SEC | May 15, 2023 | — |
| PRER14A | Filing | May 15, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 27, 2023 | — |
| 425 | Filing | Dec 27, 2022 | — |
| DFAN14A | Filing | Aug 11, 2022 | — |
| DFAN14A | Filing | Aug 3, 2022 | — |
| DFAN14A | Filing | Jul 28, 2022 | — |
| DFAN14A | Filing | Jul 22, 2022 | — |
| DFAN14A | Filing | Jul 22, 2022 | — |
| DFAN14A | Filing | Jul 21, 2022 | — |
| DEFC14A | Filing | Jul 19, 2022 | — |
| DEFC14A | Filing | Jul 19, 2022 | — |
| PRRN14A | Filing | Jul 18, 2022 | — |
| UPLOAD | Letter from the SEC | Jul 18, 2022 | — |
| PRRN14A | Filing | Jul 14, 2022 | — |
| PREC14A | Filing | Jul 8, 2022 | — |
| DFAN14A | Filing | Jun 17, 2022 | — |
| DFAN14A | Filing | May 25, 2022 | — |
| DFAN14A | Filing | May 10, 2022 | — |
| PRRN14A | Filing | May 9, 2022 | — |
| UPLOAD | Letter from the SEC | May 4, 2022 | — |
| DFAN14A | Filing | May 2, 2022 | — |
| PREC14A | Filing | Apr 28, 2022 | — |
| DFAN14A | Filing | Apr 21, 2022 | — |
| DFAN14A | Filing | Mar 16, 2022 | — |
| DFAN14A | Filing | Mar 7, 2022 | — |
| DFAN14A | Filing | Feb 28, 2022 | — |
| DFAN14A | Filing | Feb 23, 2022 | — |
| EFFECT | Filing | May 3, 2021 | — |
| CORRESP | Letter to the SEC | Apr 29, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 9, 2021 | — |
| EFFECT | Filing | Feb 14, 2019 | — |
| CORRESP | Letter to the SEC | Feb 11, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 8, 2019 | — |
| EFFECT | Filing | Feb 6, 2018 | — |
| CORRESP | Letter to the SEC | Feb 2, 2018 | — |
| UPLOAD | Letter from the SEC | Jan 30, 2018 | — |
| EFFECT | Filing | Apr 6, 2017 | — |
| CORRESP | Letter to the SEC | Apr 6, 2017 | — |
| CORRESP | Letter to the SEC | Apr 6, 2017 | — |
| CT ORDER | Filing | Mar 22, 2017 | — |
| UPLOAD | Letter from the SEC | Jan 6, 2017 | — |
| CT ORDER | Filing | Sep 12, 2016 | — |
| EFFECT | Filing | Apr 28, 2016 | — |
| CORRESP | Letter to the SEC | Apr 26, 2016 | — |
| 425 | Form 8-k | Aug 19, 2015 | — |
| 425 | Form 8-k | Aug 4, 2015 | — |
| CT ORDER | Filing | Jul 29, 2015 | — |
| EFFECT | Filing | Jul 27, 2015 | — |
| CORRESP | Letter to the SEC | Jul 23, 2015 | — |
| CORRESP | Letter to the SEC | Jul 17, 2015 | — |
| UPLOAD | Letter from the SEC | Jul 14, 2015 | — |
| CORRESP | Letter to the SEC | Jun 30, 2015 | — |
| UPLOAD | Letter from the SEC | Jun 23, 2015 | — |
| 425 | Form 8-k | May 14, 2015 | — |
| 425 | 8-k | May 12, 2015 | — |
| 425 | 8-k | Apr 6, 2015 | — |
| CT ORDER | Filing | Mar 31, 2015 | — |
| 425 | Form 8-k | Mar 6, 2015 | — |
| 425 | Form 8-k | Mar 6, 2015 | — |
| CT ORDER | Filing | Nov 4, 2014 | — |
| CT ORDER | Filing | May 13, 2014 | — |
| CT ORDER | Filing | May 13, 2014 | — |
| CT ORDER | Filing | Jan 31, 2014 | — |
| EFFECT | Filing | Dec 11, 2013 | — |
Showing 84 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GYRE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1124105
- Former names
- CATALYST BIOSCIENCES, INC. (until Oct 27, 2023); TARGACEPT INC (until Aug 19, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.